Publications by authors named "Ermacora A"

Article Synopsis
  • Researchers studied BCR::ABL1 expression in 168 chronic myeloid leukemia patients who stopped treatment with imatinib or 2G-TKIs after achieving deep molecular response.
  • Patients were categorized into two groups: those who maintained their response (group 1) and those who lost it (group 2), with group 2 showing significantly higher BCR::ABL1 RNA levels at both one and two months post-treatment.
  • A threshold value of BCR::ABL1 at one month after stopping treatment was identified, with a cut-off value of 0.0051%, showing 92.2% specificity but only 31.7% sensitivity in predicting loss of major molecular response.
View Article and Find Full Text PDF
Article Synopsis
  • Studies indicate that hepatitis C virus (HCV) may be linked to some B-cell non-Hodgkin lymphomas (B-NHL), with pegylated interferon (Peg-IFN) and ribavirin (RBV) previously effective in treatment.
  • The review finds that direct antiviral agents (DAAs) are now preferred due to their higher efficacy (95%-100% success) and better tolerability compared to older therapies.
  • Although most patients responded well to DAAs, some experienced relapse or progression of the disease, suggesting the need for further treatment options like immunotherapy or chemoimmunotherapy following successful HCV eradication.
View Article and Find Full Text PDF
Article Synopsis
  • Light-chain deposition disease (LCDD) is a rare condition characterized by the buildup of abnormal immunoglobulins that can affect various organs, mainly the kidneys.
  • A 70-year-old man presented with worsening kidney and liver function, leading to the diagnosis of LCDD after tests revealed monoclonal kappa light chains and organ infiltration.
  • Treatment with dexamethasone and bortezomib showed improvement, highlighting the need for aggressive chemotherapy in severe cases of LCDD.
View Article and Find Full Text PDF
Article Synopsis
  • Hepatitis C virus (HCV) infection affects around 170 million globally and can lead to chronic infection in about 70% of cases, which may progress to serious liver conditions and other health issues, including extra-hepatic manifestations like mixed cryoglobulinemia (MC) and non-Hodgkin lymphomas (NHL).
  • Cryoglobulinemic vasculitis (CV) can cause a range of symptoms from mild (like leg purpura and fatigue) to severe (including life-threatening complications like gastrointestinal vasculitis), and is linked to significant morbidity and mortality, often necessitating treatment post-antiviral therapy.
  • New direct antiviral agents (DAAs) show high
View Article and Find Full Text PDF

Hepatitis B virus (HBV) is a hepatotropic virus that causes hepatitis, cirrhosis and hepatocellular carcinoma. Twenty percent of HBV patients may develop extra-hepatic manifestations, such as polyarthritis nodosa, glomerulonephritis, dermatitis, poly-arthralgia and arthritis, and aplastic anemia. The association of HBV and cryoglobulinemic vasculitis (CV) has been highlighted by several epidemiological investigations.

View Article and Find Full Text PDF

Despite widespread use of decitabine to treat acute myeloid leukaemia (AML), data on its effectiveness and safety in the real-world setting are scanty. Thus, to analyze the performance of decitabine in clinical practice, we pooled together patient-level data of three multicentric observational studies conducted since 2013 throughout Italy, including 306 elderly AML patients (median age 75 years), unfit for intensive chemotherapy, treated with first-line decitabine therapy at the registered schedule of 20 mg/m /iv daily for 5 days every 4 weeks. Overall response rate (ORR), overall survival (OS) curves, and multivariate hazard ratios (HRs) of all-cause mortality were computed.

View Article and Find Full Text PDF

Acquired haemophilia A (AHA) is a rare bleeding disorder due to autoantibodies directed against coagulation factor VIII. The treatment is based on recombinant activated factor VII and activated prothrombin complex concentrate. However, mainly in older patients, severe thrombotic complications have been reported.

View Article and Find Full Text PDF
Article Synopsis
  • DAC (Decitabine) is a hypomethylating agent used as a treatment for acute myeloid leukemia (AML), particularly beneficial for elderly patients who can't tolerate intensive chemotherapy, but its efficacy and safety in real-world settings are not well-established.
  • A study reviewing 104 AML patients treated with DAC across eight Italian centers found that 75% received DAC as their initial treatment, with the median age being 72.5 years, and revealed significant patient characteristics like high bone marrow blast counts and varying treatment backgrounds.
  • The results showed an overall response rate of 33%, with a notable difference between first-line treatment patients (42% response) and those receiving DAC as salvage therapy (14%), while factors like achieving complete or partial remission
View Article and Find Full Text PDF

Diario della Salute [My Health Diary] is a school-based program designed to enhance the subjective well-being and health of 12- to 13-year-old students. We hypothesized that providing students with the social and emotional skills to fulfill their potential and deal with common developmental tasks of adolescence (e.g.

View Article and Find Full Text PDF

Lipid oxidation is one of the most important reasons for the compromised shelf life of food emulsions. A major bottleneck in unravelling the underlying mechanisms is the lack of methods that provide a rapid, quantitative, and comprehensive molecular view on lipid oxidation in these heterogeneous systems. In this study, the unbiased and quantitative nature of H NMR was exploited to assess lipid oxidation products in mayonnaise, a particularly oxidation-prone food emulsion.

View Article and Find Full Text PDF

Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation.

View Article and Find Full Text PDF

The toxicological relevance and widespread occurrence of fatty acid esters of 2-chloropropane-1,3-diol (2-MCPD) and 3-chloropropane-1,2-diol (3-MCPD) in refined oils and fats have recently triggered an interest in the mechanism of formation and decomposition of these contaminants during oil processing. In this work, the effect of the main precursors, namely acylglycerols and chlorinated compounds, on the formation yield of MCPD esters was investigated in model systems simulating oil deodorization. The composition of the oils was modified by enzymatic hydrolysis, silica gel purification and application of various refining steps prior to deodorization (namely degumming, neutralization, bleaching).

View Article and Find Full Text PDF

Substantial progress has been recently made in the development and optimisation of analytical methods for the quantification of 2-MCPD, 3-MCPD and glycidyl esters in oils and fats, and there are a few methods currently available that allow a reliable quantification of these contaminants in bulk oils and fats. On the other hand, no standard method for the analysis of foodstuffs has yet been established. The aim of this study was the development and validation of a new method for the simultaneous quantification of 2-MCPD, 3-MCPD and glycidyl esters in oil-based food products.

View Article and Find Full Text PDF

The establishment of effective strategies for the mitigation of 3-MCPD esters in refined vegetable oils is restricted by limited knowledge of their mechanisms of formation and decomposition. In order to gain better understanding on the thermal stability of these compounds, a model system for mimicking oil refining conditions was developed. Pure 3-MCPD esters (3-MCPD dipalmitate and 3-MCPD dilaurate) were subjected to thermal treatment (180-260°C) and the degradation products where monitored over time (0-24h).

View Article and Find Full Text PDF

Glycidyl esters (GE), fatty acid esters of glycidol, are process contaminants formed during edible oil processing. A novel direct method for the determination of intact GE in oils and fats based on gas chromatography-mass spectrometry (GC-MS) is presented. The method consists of a simple extraction step of GE from the lipid matrix, purification of the extract and isolation of GE by normal phase liquid chromatography (NPLC).

View Article and Find Full Text PDF
Article Synopsis
  • P-glycoprotein (P-gp), lung resistance-related protein (LRP), and multidrug resistance-associated protein (MRP) were evaluated in 95 cases of adult acute lymphoblastic leukemia (ALL) to understand their impact on drug accumulation and treatment response.
  • Almost half of the patients showed P-gp positivity, while LRP and MRP expressions were much lower, with many patients not overexpressing any of these proteins.
  • P-gp overexpression was linked to a reduced ability to accumulate the chemotherapy drug daunorubicin, resulting in poorer treatment outcomes and shorter disease-free survival, whereas the roles of LRP and MRP remain unclear due to their limited presence.
View Article and Find Full Text PDF

In this work three human cell lines with multidrug resistance (MDR) caused by a P-glycoprotein (PGP) overexpression, CEM VLB, HL60 DNR, LOVO DX and two cell lines with MDR associated with a multidrug related protein (MRP) or a lung resistance-related protein (LRP) overexpression named GLC4 ADR and SW1573/2R120 were tested for Amifostine protection against Daunorubicin, Doxorubicin, Idarubicin and Mitoxantrone toxicity. This class of anticancer agents was chosen because they are commonly used in the first line treatments of acute leukemias where a PGP, an LRP or an MRP overexpression often occurs even at onset. A 7-day incubation with escalating doses of anticancer agents with or without a 15 minute preincubation in Amifostine or its active metabolite WR-1065 were used.

View Article and Find Full Text PDF

Liposomal formulations of anthracyclines have been developed to increase their delivery to solid tumors while reducing toxicity in normal tissues. DaunoXome (DNX, NeXstar) is a liposomal-encapsulated preparation of daunorubicin registered for treatment of Kaposi's sarcoma that during prior in vitro studies showed a toxicity to leukemic cells at least comparable to that of free daunorubicin. The aim of our study was to determine DNX pharmacokinetics in 11 poor-risk patients with acute leukemia treated with DNX 60 mg/m2 IV on days 1, 3, and 5.

View Article and Find Full Text PDF

We analysed the expression of three drug transporter proteins [p-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP1)] involved in anthracycline resistance that are frequently overexpressed in poor-risk adult acute non-lymphocytic leukaemia (ANLL), in 23 acute promyelocytic leukaemia (APL) patients at onset managed at a single institution. Cellular daunorubicin accumulation was also evaluated. At onset, no case had PGP or MRP1 expression that exceeded that of non-multidrug-resistant (MDR) cell lines.

View Article and Find Full Text PDF

Reactivation of hepatitis B virus in patients receiving chemotherapy for non-Hodgkin's lymphoma (NHL) may give rise to hepatitis, hepatic failure and death, and prevent further chemotherapy. We report four patients with NHL in whom hepatitis flare-up was observed after two (three patients) and six (one patient) cycles of chemotherapy. After spontaneous recovery, they were treated with Lamivudine (100 mg/day), which enabled completion of chemotherapy without further hepatitis B reactivation.

View Article and Find Full Text PDF

Background: Laparoscopic splenectomy (LS) is becoming the gold standard in the treatment of several splenic diseases. Shorter postoperative stay and more rapid return to full activity are the primary advantages of LS.

Methods: Prospective data collection of 44 consecutive LS (group 1) and comparison with a historical control group of 56 consecutive open splenectomies (OS) (group 2) were performed for hematologic diseases.

View Article and Find Full Text PDF